284 related articles for article (PubMed ID: 16825015)
21. Genomic damage and malignancy in end-stage renal failure: do advanced glycation end products contribute?
Sebeková K; Wagner Z; Schupp N; Boor P
Kidney Blood Press Res; 2007; 30(1):56-66. PubMed ID: 17261927
[TBL] [Abstract][Full Text] [Related]
22. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients.
Piroddi M; Depunzio I; Calabrese V; Mancuso C; Aisa CM; Binaglia L; Minelli A; Butterfield AD; Galli F
Amino Acids; 2007; 32(4):573-92. PubMed ID: 17356806
[TBL] [Abstract][Full Text] [Related]
23. Kinetic analysis of furosine and pentosidine in CAPD patients.
Kumano K; Yokota S; Sakai T; Kobayashi N; Yoshida A; Yoshihara T; Shibata K; Izumi G; Wang H
Adv Perit Dial; 1997; 13():53-7. PubMed ID: 9360651
[TBL] [Abstract][Full Text] [Related]
24. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.
Tanaka K; Tani Y; Asai J; Nemoto F; Kusano Y; Suzuki H; Hayashi Y; Asahi K; Katoh T; Miyata T; Watanabe T
Nephrol Dial Transplant; 2011 Jan; 26(1):214-20. PubMed ID: 20591816
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis.
Van Biesen W; Verbeke F; Vanholder R
Nephrol Dial Transplant; 2007 Jan; 22(1):53-8. PubMed ID: 17050633
[No Abstract] [Full Text] [Related]
26. Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection.
Ahmed N; Mirshekar-Syahkal B; Kennish L; Karachalias N; Babaei-Jadidi R; Thornalley PJ
Mol Nutr Food Res; 2005 Jul; 49(7):691-9. PubMed ID: 15945118
[TBL] [Abstract][Full Text] [Related]
27. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it.
Ahmed N; Lüthen R; Häussinger D; Sebeková K; Schinzel R; Voelker W; Heidland A; Thornalley PJ
Ann N Y Acad Sci; 2005 Jun; 1043():718-24. PubMed ID: 16037298
[TBL] [Abstract][Full Text] [Related]
28. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update.
Lapolla A; Fedele D; Seraglia R; Traldi P
Mass Spectrom Rev; 2006; 25(5):775-97. PubMed ID: 16625652
[TBL] [Abstract][Full Text] [Related]
29. Detection of Free Advanced Glycation End Products in Vivo during Hemodialysis.
Hohmann C; Liehr K; Henning C; Fiedler R; Girndt M; Gebert M; Hulko M; Storr M; Glomb MA
J Agric Food Chem; 2017 Feb; 65(4):930-937. PubMed ID: 28112514
[TBL] [Abstract][Full Text] [Related]
30. Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency.
Sebeková K; Klenovicsová K; Ferenczová J; Hedvig J; Podracká L; Heidland A
J Ren Nutr; 2012 Jan; 22(1):143-8. PubMed ID: 22200432
[TBL] [Abstract][Full Text] [Related]
31. Advanced glycation in uraemic toxicity.
van Ypersele de Strihou C
EDTNA ERCA J; 2003; 29(3):148-50. PubMed ID: 14552090
[TBL] [Abstract][Full Text] [Related]
32. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
33. Advanced glycation endproducts in chronic heart failure.
Smit AJ; Hartog JW; Voors AA; van Veldhuisen DJ
Ann N Y Acad Sci; 2008 Apr; 1126():225-30. PubMed ID: 18448821
[TBL] [Abstract][Full Text] [Related]
34. RAGE expression in the human peritoneal membrane.
Kihm LP; Wibisono D; Müller-Krebs S; Pfisterer F; Morath C; Gross ML; Morcos M; Seregin Y; Bierhaus A; Nawroth PP; Zeier M; Schwenger V
Nephrol Dial Transplant; 2008 Oct; 23(10):3302-6. PubMed ID: 18477569
[TBL] [Abstract][Full Text] [Related]
35. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
Higuchi C; Nishimura H; Sanaka T
Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis.
Segall L; Covic A
Nephrol Dial Transplant; 2007 Jan; 22(1):59-63. PubMed ID: 17099221
[No Abstract] [Full Text] [Related]
37. The prescription of peritoneal dialysis.
Tzamaloukas AH; Raj DS; Onime A; Servilla KS; Vanderjagt DJ; Murata GH
Semin Dial; 2008; 21(3):250-7. PubMed ID: 18248525
[TBL] [Abstract][Full Text] [Related]
38. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis.
Agalou S; Ahmed N; Dawnay A; Thornalley PJ
Biochem Soc Trans; 2003 Dec; 31(Pt 6):1394-6. PubMed ID: 14641071
[TBL] [Abstract][Full Text] [Related]
39. Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis.
Ahmed N; Thornalley PJ; Lüthen R; Häussinger D; Sebekova K; Schinzel R; Voelker W; Heidland A
J Hepatol; 2004 Dec; 41(6):913-9. PubMed ID: 15582123
[TBL] [Abstract][Full Text] [Related]
40. Effect of different hemodialysis regimens on genomic damage in end-stage renal failure.
Schupp N; Stopper H; Rutkowski P; Kobras K; Nebel M; Bahner U; Vienken J; Heidland A
Semin Nephrol; 2006 Jan; 26(1):28-32. PubMed ID: 16412822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
